Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
CP3
1 other identifier
interventional
520
1 country
10
Brief Summary
The goal of this research is to test a novel centralized care coordinator program to assist patients with psoriatic disease in lowering their risk of cardiovascular disease through the application of standard of care approaches to improving modifiable cardiovascular risk factors.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started Jun 2023
Typical duration for not_applicable
10 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 25, 2023
CompletedStudy Start
First participant enrolled
June 15, 2023
CompletedFirst Posted
Study publicly available on registry
June 18, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
July 1, 2026
March 27, 2026
March 1, 2026
3 years
May 25, 2023
March 25, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Change in LDL
Change in LDL cholesterol
6 months
Secondary Outcomes (21)
Addition of new medication
6 months
Change in 10-year cardiovascular (CV) risk
6 months
30% LDL reduction
6 months
50% LDL reduction
6 months
LDL reduction under 100
6 months
- +16 more secondary outcomes
Study Arms (1)
Care Coordination
OTHERInterventions
A centralized care coordinator at the National Psoriasis Foundation will provide evidence-based education regarding a heart healthy lifestyle (i.e., diet, exercise, smoking cessation) and guidance from the American Heart Association/American College of Cardiology regarding management of dyslipidemia and hypertension. This information will be conveyed to a primary care provider of the patient's preference.
Eligibility Criteria
You may qualify if:
- Willing and able to provide informed consent
- Male or female aged 40-75
- Being seen by a dermatology provider in routine care for the primary encounter diagnosis of psoriasis
You may not qualify if:
- Currently taking a prescription lipid lowering medication
- Pregnant or planning pregnancy in the next 6 months
- Has a known history of cardiovascular disease (MI, Stroke, coronary artery, cerebrovascular, or peripheral vascular disease)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- University of Pennsylvanialead
- National Psoriasis Foundationcollaborator
Study Sites (10)
Johnson Dermatology
Fort Smith, Arkansas, 72916, United States
Dawes Fretzin Clinical Research
Columbus, Indiana, 47201, United States
Dawes Fretzin Clinical Research
Indianapolis, Indiana, 46250, United States
MiSkinCenter
Northville, Michigan, 48167, United States
SUNY Downstate
Brooklyn, New York, 11203, United States
City Dermatology
Bensalem, Pennsylvania, 19020, United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
University of Utah
Salt Lake City, Utah, 84112, United States
University of Virginia
Charlottesville, Virginia, 22903, United States
Bellevue Dermatology Clinic
Bellevue, Washington, 98004, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 25, 2023
First Posted
June 18, 2023
Study Start
June 15, 2023
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
July 1, 2026
Last Updated
March 27, 2026
Record last verified: 2026-03
Data Sharing
- IPD Sharing
- Will not share